Business Description
RenovoRx Inc
NAICS : 541714
SIC : 2834
ISIN : US75989R1077
Description
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -2.05 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -42.6 | |||||
| 3-Year EPS without NRI Growth Rate | -36.7 | |||||
| 3-Year FCF Growth Rate | -33.3 | |||||
| 3-Year Book Growth Rate | 45.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 81.8 | |||||
| 9-Day RSI | 72.78 | |||||
| 14-Day RSI | 64.48 | |||||
| 6-1 Month Momentum % | 10.74 | |||||
| 12-1 Month Momentum % | -56.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.25 | |||||
| Quick Ratio | 1.25 | |||||
| Cash Ratio | 1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -672.01 | |||||
| ROA % | -221.23 | |||||
| ROIC % | -3559.03 | |||||
| ROC (Joel Greenblatt) % | -33517.65 | |||||
| ROCE % | -350.88 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -2.94 | |||||
| EV-to-EBITDA | -2.94 | |||||
| EV-to-Forward-EBITDA | -3.45 | |||||
| EV-to-FCF | -3.27 | |||||
| Earnings Yield (Greenblatt) % | -34.01 | |||||
| FCF Yield % | -29.54 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RNXT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
RenovoRx Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.01 | ||
| Beta | 0 | ||
| Volatility % | 282.11 | ||
| 14-Day RSI | 64.48 | ||
| 14-Day ATR ($) | 0.114181 | ||
| 20-Day SMA ($) | 1.240035 | ||
| 12-1 Month Momentum % | -56.51 | ||
| 52-Week Range ($) | 0.5306 - 3.29 | ||
| Shares Outstanding (Mil) | 23.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
RenovoRx Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
RenovoRx Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
RenovoRx Inc Frequently Asked Questions
What is RenovoRx Inc(RNXT)'s stock price today?
The current price of RNXT is $1.45. The 52 week high of RNXT is $3.29 and 52 week low is $0.53.
When is next earnings date of RenovoRx Inc(RNXT)?
The next earnings date of RenovoRx Inc(RNXT) is 2024-05-15 Est..
Does RenovoRx Inc(RNXT) pay dividends? If so, how much?
RenovoRx Inc(RNXT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers